Eisai

Contact
eisai.at
+4315351980-0

Eisai GmbH

Leonard-Bernstein-Straße 10
1220 Wien
Austria
+4315351980-0
eisai.at
Contact
Profile News
Contact

About Eisai

Eisai is one of the leading research-oriented pharmaceutical companies in the global pharmaceutical market. With innovative products for diseases of the central nervous system and the gastrointestinal tract, Eisai helps to improve the quality of life of patients and their families.

Read more about Eisai

Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.

Read more
Facts about Eisai
  • Industry : Pharma

News about Eisai

Eisai

09-Nov-2018 | manufacturing

Eisai commences full-scale operation of new production site

Strengthening in-house domestic production system in China

Read news
Eisai

15-Jul-2013 | research and development

Swissmedic Approves Zonegran (zonisamide) Monotherapy Treatment for Epilepsy

Zonegran (zonisamide) has today been approved by Swissmedic for the monotherapy treatment of partial seizures (with or without secondary generalisation) in ...

Read news
Eisai

26-Apr-2011 | research and development

Eisai: Halaven Receives Approval in Japan for the Treatment of Inoperable and Recurrent Breast Cancer

Eisai Co., Ltd. announced that it has received approval to market its anticancer Halaven(R) Injection 1mg (eribulin mesylate) in Japan for the treatment of ...

Read news
Eisai

24-Jan-2011 | research and development

Eisai's Halaven Receives CHMP Positive Opinion for use in Metastatic Breast Cancer

CHMP Opinion Based on Positive EMBRACE Study Data

Read news
Eisai

27-Aug-2010 | research and development

Eisai Announces Positive Phase III Trial Results for Perampanel in Partial Epilepsy

Eisai announced the results of a Phase III study for the investigational compound perampanel (E2007), a first-in-class, highly selective non-competitive ...

Read news
Eisai

19-Oct-2009 | business & finance

Eisai Opens Regional Office in Bahrain

Eisai Co., Ltd. announced the opening of a regional office in Bahrain. The new office has been established as a branch of its Asian headquarters Eisai Asia ...

Read news
Eisai

24-Jul-2009 | research and development

Eisai Receives Approval for a New Oral Jelly Formulation of Aricept for the Treatment of Alzheimer’s Disease in Japan

Eisai Co., Ltd. announced that the Company had received approval for a new oral jelly formulation of Aricept® (donepezil hydrochloride) for the treatment ...

Read news
Eisai

19-Aug-2008 | business & finance

SymBio Pharmaceuticals and Eisai Sign License Agreement for bendamustine hydrochloride (SyB L-0501)

SymBio Pharmaceuticals Limited. and Eisai Co., Ltd. announced that the companies have concluded the license agreement for the co-development and ...

Read news
Show more news about Eisai

Here you will find Eisai GmbH